Quick Answer
Passage BIO, Inc. reported Operating Income Loss of -$49.30 million for the year ending 2025.
- Passage BIO, Inc. showed an increase of +30.0% in Operating Income Loss from 2024 to 2025.
- This data is from Passage BIO, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: -$7.77 million | Q3 2019: -$11.64 million | Q1 2020: -$17.91 million | Q2 2020: -$27.30 million | Q3 2020: -$28.63 million | Q1 2021: -$38.93 million | Q2 2021: -$48.53 million | Q3 2021: -$47.10 million | Q1 2022: -$42.81 million | Q2 2022: -$39.81 million | Q3 2022: -$27.53 million | Q1 2023: -$35.88 million | Q2 2023: -$25.39 million | Q3 2023: -$28.67 million | Q1 2024: -$18.05 million | Q2 2024: -$17.38 million | Q3 2024: -$20.70 million | Q1 2025: -$16.46 million | Q2 2025: -$10.33 million | Q3 2025: -$8.66 million.
- Over the full 7 years of available data (2019 to 2025), Passage BIO, Inc.'s Operating Income Loss has declined by 32.6%.
- Historical annual values: Fiscal year 2025: -$49.30 million | Fiscal year 2024: -$70.40 million | Fiscal year 2023: -$108.39 million | Fiscal year 2022: -$138.39 million | Fiscal year 2021: -$185.73 million | Fiscal year 2020: -$112.90 million | Fiscal year 2019: -$37.19 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: